With the wild success of glucagon-like peptide-1 (GLP-1) drugs, Amylyx Pharmaceuticals is looking to explore the field as it has bought out avexitide, a Phase III ready GLP-1 receptor antagonist, for $35 million in an auction last month from bankrupt Eiger BioPharmaceuticals
Patients enrolled in the trial had biopsy proven NASH/borderline NASH (NAS 4) without cirrhosis (n = 283)
If you are looking for a weight loss treatment that can finally help you take control of your appetite, work with your busy schedule, and possibly offer beneficial health perks besides weight loss, GLP-1 injections may be just what you need
Buyers are responsible for confirming import rules, registration requirements, formulation permissions, end-use requirements, and local regulatory obligations before procurement
Your health goals and diagnosis will determine which is appropriate